WO2015093567A1 - 疼痛に関する化合物及び医薬組成物 - Google Patents
疼痛に関する化合物及び医薬組成物 Download PDFInfo
- Publication number
- WO2015093567A1 WO2015093567A1 PCT/JP2014/083569 JP2014083569W WO2015093567A1 WO 2015093567 A1 WO2015093567 A1 WO 2015093567A1 JP 2014083569 W JP2014083569 W JP 2014083569W WO 2015093567 A1 WO2015093567 A1 WO 2015093567A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- pain
- substituted
- compound
- unsubstituted
- Prior art date
Links
- 0 *CN1/C2=C/C(*)/C=C/*/C=C2/SC1=CC(*)=O Chemical compound *CN1/C2=C/C(*)/C=C/*/C=C2/SC1=CC(*)=O 0.000 description 1
- SUYWQHRJAVBMIQ-QPEQYQDCSA-N CCN1c(ccc(OC)c2)c2S/C1=C\C(C)=O Chemical compound CCN1c(ccc(OC)c2)c2S/C1=C\C(C)=O SUYWQHRJAVBMIQ-QPEQYQDCSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present disclosure relates to pain-related compounds and pharmaceutical compositions and uses thereof.
- Pain is defined as an unpleasant sensory or emotional experience with actual or potential tissue damage, or can be described as such damage.
- Inflammatory pain is nociceptive pain via nociceptors and can be said to be pain caused by inflammatory mediators released to the site of tissue damage.
- the mechanism of inflammatory pain is considered as follows. That is, when tissue is damaged and inflammation occurs, pain-inducing substances such as bradykinin, ATP, and protons and / or prostaglandins, serotonin, histamine, inflammatory cytokines, and the like are released, and spontaneous pain occurs continuously.
- hypersensitivity results from hypersensitivity of nociceptors.
- phosphorylation of ion channels, particularly TRPV1 channel known as capsaicin receptor has been reported.
- neuropathic pain can be defined as pain caused by lesions or diseases of the somatosensory nervous system (2011 International Pain Society). It is estimated that there are millions of patients with neuropathic pain in Japan. Pain that does not involve nociceptor excitement and involves plastic changes in the peripheral or central nerves. Neuropathic pain can be caused by ectopic firing of peripheral nerves, neuroanatomical reconstruction in peripheral nerves and dorsal horn of spinal cord, suppression of descending inhibitory system, activation of glial cells in spinal dorsal horn, etc. It has been reported.
- Patent Document 1 discloses methods and compositions for treating pain.
- Patent Document 2 discloses a medical composition that suppresses abnormal splicing that occurs when kinase is excessively induced.
- the present disclosure in one aspect, provides compounds and pharmaceutical compositions related to pain, and uses thereof.
- the present disclosure relates to a compound represented by the following formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof.
- W, X, Y, and Z are each independently a hydrogen atom, a halogen atom, a substituted or unsubstituted amino group, an azide group, a cyano group, a nitro group, a hydroxyl group, a linear or branched group having 1 to 6 carbon atoms.
- arylthio group substituted or unsubstituted heteroarylthio group having 1 to 6 carbon atoms
- a substituted or unsubstituted heteroarylthio group a linear or branched or cyclic alkyl group having 1 to
- the present disclosure relates to a pharmaceutical composition containing, as an active ingredient, a compound represented by the formula (I) or a prodrug thereof or a pharmaceutically acceptable salt thereof according to the present disclosure in one or a plurality of embodiments.
- the present disclosure provides a compound represented by formula (I) according to the present disclosure or a prodrug thereof, or a pharmaceutically acceptable product thereof, for producing a pharmaceutical composition according to the present disclosure. Relates to the use of salt.
- the present disclosure in one or more embodiments, relates to a method for improving, suppressing progression, and / or treating pain, comprising administering a pharmaceutical composition according to the present disclosure to a subject in need thereof.
- the present disclosure is a method for improving pain, suppressing progression, and / or treatment, and includes administering a pharmaceutical composition according to the present disclosure to a subject in need thereof.
- the present invention relates to the use of a compound represented by formula (I) or a prodrug thereof or a pharmaceutically acceptable salt thereof according to the present disclosure, or a pharmaceutical composition according to the present disclosure.
- FIG. 1 is an example of a graph confirming the effect of treatment with pain of Compound 1 in a carrageenin-induced inflammatory pain model mouse.
- Compound 1 was orally administered to evaluate the therapeutic effect of mechanical allodynia (pain to mechanical stimulation).
- the vertical axis of the graph represents the threshold value (load) of the escape reflex behavior with respect to the mechanical stimulation of the von Frey filament.
- FIG. 2 is an example of a graph confirming the effect of compound 1 pain treatment in carrageenin-induced inflammatory pain model mice.
- Compound 1 was orally administered to evaluate the therapeutic effect of thermal hypersensitivity (pain to thermal stimulation).
- the vertical axis of the graph represents the latency (time) until the escape reflex behavior with respect to the thermal stimulus.
- FIG. 1 is an example of a graph confirming the effect of treatment with pain of Compound 1 in a carrageenin-induced inflammatory pain model mouse.
- Compound 1 was orally administered to evaluate the therapeutic effect of thermal hypersensitivity (pain to thermal stimulation).
- FIG. 3 is an example of a graph confirming the effect of compound 2 pain treatment in a carrageenin-induced inflammatory pain model mouse.
- Compound 2 was administered intrathecally and the response to mechanical and thermal stimuli was examined.
- FIG. 3A is an example of a result of examining a threshold value of escape reflex behavior with respect to a mechanical stimulus
- FIG. 4 is an example of a graph confirming the effect of compound 3 pain treatment in a model mouse with inflammatory pain induced by complete Freund's adjuvant.
- Compound 3 was administered intrathecally and the threshold to the escape reflex behavior for mechanical stimulation was examined.
- FIG. 5 is an example of a graph confirming the effect of compound 4 pain treatment in a carrageenin-induced inflammatory pain model mouse.
- FIG. 5A is an example of the result of examining the threshold of escape reflex behavior for mechanical stimulation
- FIG. 5B is the result of examining the latency to thermal stimulation.
- FIG. 6 is an example of a graph confirming the effect of compound 5 pain treatment in a carrageenin-induced inflammatory pain model mouse.
- Compound 5 was administered intrathecally, and the latency (time) until the escape reflex behavior in response to thermal stimulation was examined.
- FIG. 7 is an example of a graph confirming the effect of compound 6 pain treatment in a carrageenin-induced inflammatory pain model mouse.
- Compound 6 was administered intrathecally and the latency (time) until the escape reflex behavior to the heat stimulus was examined.
- FIG. 8 is an example of a graph in which the effect on the therapeutic effect of pain is evaluated by simultaneously administering Compound 1 and an opioid antagonist to a carrageenin-induced inflammatory pain model mouse.
- Compound 1 and an opioid antagonist were intraperitoneally administered to examine the response to mechanical stimulation.
- W, X, Y and Z are each independently a hydrogen atom, a halogen atom, a substituted or unsubstituted amino group, an azide group, a cyano group, a nitro group, a hydroxyl group, a substituted or unsubstituted group.
- Examples of the straight or branched alkyl group having 1 to 6 carbon atoms in W, X, Y, and Z include, in one or more embodiments, a methyl group, an ethyl group, a 1-propyl group, a 2-propyl group, 2-methyl-1-propyl group, 2-methyl-2-propyl group, 1-butyl group, 2-butyl group, 1-pentyl group, 2-pentyl group, 3-pentyl group, 2-methyl-1-butyl Group, 3-methyl-1-butyl group, 2-methyl-2-butyl group, 3-methyl-2-butyl group, 2,2-dimethyl-1-propyl group, 1-hexyl group, 2-hexyl group Group, 3-hexyl group, 2-methyl-1-pentyl group, 3-methyl-1-pentyl group, 4-methyl-1-pentyl group, 2-methyl-2-pentyl group, 3-methyl-2- Pentyl group, 4-methyl-2-pentyl group, 2-methyl-3
- examples of the cyclic alkyl group having 1 to 6 carbon atoms in W, X, Y, and Z include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl in one or more embodiments.
- Heteroaryl in W, X, Y, and Z is, in one or more embodiments, a 5- to 6-membered monocyclic group containing 1 to 2 nitrogen atoms , 5- to 6-membered monocyclic group containing 1 to 2 nitrogen atoms and 1 oxygen atom or 1 sulfur atom, 5 membered monocyclic containing 1 oxygen atom or 1 sulfur atom And a bicyclic group containing 1 to 4 nitrogen atoms and condensed with a 6-membered ring and a 5- or 6-membered ring.
- the aryl group for R 1 and R 2 include aryl groups having 10 or less carbon atoms such as a phenyl group and a naphthyl group.
- the substituents for W, X, Y, and Z may be one or the same or different and may be plural, and in one or more embodiments, a halogen atom, a cyano group, a trifluoromethyl group, a nitro group, a hydroxyl group , Methylenedioxy group, lower alkyl group, lower alkoxy group, benzyloxy group, lower alkanoyloxy group, amino group, mono-lower alkylamino group, di-lower alkylamino group, carbamoyl group, lower alkylaminocarbonyl group, di-lower alkyl Examples thereof include an aminocarbonyl group, a carboxyl group, a lower alkoxycarbonyl group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a lower alkanoylamino group, and a lower alkylsulfonamide group.
- halogen atoms include fluorine, chlorine, bromine, or iodine atoms in one or more embodiments.
- lower alkyl is a linear or branched alkyl group having 1 to 6 carbon atoms in one or more embodiments.
- the compound represented by the formula (I) is a compound represented by the following formula (II) in one or a plurality of non-limiting embodiments.
- X 1 and Y 1 are each independently a halogen atom, a substituted or unsubstituted linear or branched or cyclic alkyl group having 1 to 6 carbon atoms
- Z 1 and W 1 Each independently represents a hydrogen atom, a halogen atom, a hydroxyl group, a linear or branched or cyclic alkyloxy group having 1 to 6 carbon atoms, a substituted or unsubstituted linear or branched group having 1 to 6 carbon atoms, or It is a cyclic alkyl group.
- substituent in X 1 , Y 1 , Z 1 and W 1 include the above-described substituents.
- the compound represented by the formula (II) is such that X 1 and Y 1 are alkyl groups having 1 to 4 carbon atoms, and Z 1 is a halogen atom, a hydroxyl group, or 1 to 4 carbon atoms. And W 1 is a hydrogen atom.
- Examples of the compound represented by the formula (I) or (II) include, but are not limited to, the following compounds.
- the compounds represented by the formulas (I) and (II) may be used in one or more embodiments in the case where an asymmetric carbon atom is present and / or a stereoisomer is present. It is a mixture or isolated.
- the “prodrug” includes, in one or a plurality of embodiments, those that are easily hydrolyzed in vivo and regenerate the compound represented by the formula (I), such as a compound having a carboxyl group. If present, there may be mentioned a compound in which the carboxyl group is an alkoxycarbonyl group, a compound in which the alkylthiocarbonyl group is formed, or a compound in which the alkylaminocarbonyl group is formed.
- a compound having an amino group a compound in which the amino group is substituted with an alkanoyl group to become an alkanoylamino group, a compound in which the amino group is substituted with an alkoxycarbonyl group to become an alkoxycarbonylamino group, an acyloxymethylamino group, Or a compound that has become hydroxylamine.
- a compound having a hydroxyl group a compound in which the hydroxyl group is substituted with the acyl group to become an acyloxy group, a compound that has become a phosphate ester, or a compound that has become an acyloxymethyloxy group can be given.
- alkyl moiety of the group used for forming a prodrug examples include the alkyl group, and the alkyl group may be substituted (for example, with an alkoxy group having 1 to 6 carbon atoms).
- the alkyl group may be substituted (for example, with an alkoxy group having 1 to 6 carbon atoms).
- lower alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, methoxymethoxycarbonyl, ethoxymethoxy, etc.
- Examples include lower (eg, having 1 to 6 carbon atoms) alkoxycarbonyl substituted with an alkoxy group such as carbonyl, 2-methoxyethoxycarbonyl, 2-methoxyethoxymethoxycarbonyl, and pivaloyloxymethoxycarbonyl.
- the “pharmaceutically acceptable salt” includes a pharmaceutically, pharmacologically, and / or pharmaceutically acceptable salt.
- an inorganic acid salt, an organic acid salt, an inorganic base salt, an organic base examples include salts, acidic or basic amino acid salts and the like.
- Preferable examples of the inorganic acid salt include hydrochloride, hydrobromide, sulfate, nitrate, phosphate and the like, and preferable examples of the organic acid salt include, for example, acetate, succinate, Examples thereof include fumarate, maleate, tartrate, citrate, lactate, stearate, benzoate, methanesulfonate, and p-toluenesulfonate.
- the inorganic base salt include alkali metal salts such as sodium salt and potassium salt, alkaline earth metal salts such as calcium salt and magnesium salt, aluminum salt and ammonium salt.
- the organic base salt include diethylamine salt, diethanolamine salt, meglumine salt, N, N′-dibenzylethylenediamine salt and the like.
- Preferred examples of the acidic amino acid salt include aspartate and glutamate.
- Preferable examples of the basic amino acid salt include arginine salt, lysine salt, ornithine salt and the like.
- the “salt of a compound” may include a hydrate that can be formed by absorbing moisture when the compound is left in the air. Further, in the present disclosure, the “salt of a compound” may include a solvate that can be formed by absorbing a certain kind of other solvent.
- the present disclosure relates to a pharmaceutical composition
- a pharmaceutical composition comprising a compound represented by formula (I) or a prodrug thereof, or a pharmaceutically acceptable salt thereof as an active ingredient.
- the compound represented by the formula (I) or the pharmaceutical composition according to the present disclosure may be used for the purpose of improving pain, suppressing progression, and / or treatment.
- the compound represented by formula (I) or the pharmaceutical composition according to the present disclosure may be used for analgesic in one or more embodiments.
- Analgesia includes pain relief.
- pain is inflammatory pain or neuropathic pain classified pathophysiologically in one or more embodiments.
- pain refers to acute pain, inflammatory pain, visceral pain, breakthrough pain, nociceptive pain, neuropathic pain, classified according to time course or mechanism in one or more embodiments, Chronic pain or cancer-related pain.
- the “pharmaceutical composition” may be a dosage form suitable for an administration form by applying a well-known formulation technique in one or a plurality of embodiments.
- the dosage form include, but are not limited to, oral administration in a dosage form such as a tablet, capsule, granule, powder, pill, troche, syrup, and liquid.
- parenteral administration in dosage forms such as injections, liquids, aerosols, suppositories, patches, lotions, liniments, ointments, eye drops and the like can be mentioned.
- These preparations can be produced by known methods using additives such as, but not limited to, excipients, lubricants, binders, disintegrants, stabilizers, flavoring agents, and diluents.
- the pharmaceutical composition according to the present disclosure does not include other active ingredients having a therapeutic (or analgesic) effect, or further includes one or a plurality of active ingredients.
- excipient examples include, but are not limited to, starch such as starch, potato starch, and corn starch, lactose, crystalline cellulose, calcium hydrogen phosphate, and the like.
- coating agent examples include, but are not limited to, ethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, shellac, talc, carnauba wax, paraffin, and the like.
- binder include, but are not limited to, polyvinyl pyrrolidone, macrogol and the same compound as the excipient.
- disintegrant examples include, but are not limited to, compounds similar to the excipients and chemically modified starch and celluloses such as croscarmellose sodium, sodium carboxymethyl starch, and crosslinked polyvinylpyrrolidone.
- stabilizer examples include, but are not limited to, paraoxybenzoates such as methylparaben and propylparaben; alcohols such as chlorobutanol, benzyl alcohol, and phenylethyl alcohol; benzalkonium chloride; phenol, cresol Mention may be made of such phenols; thimerosal; dehydroacetic acid; and sorbic acid.
- flavoring agent examples include, but are not limited to, sweeteners, acidulants, and fragrances that are commonly used.
- the solvent is not limited to these, but ethanol, phenol, chlorocresol, purified water, distilled water and the like can be used, and a surfactant or an emulsifier can also be used as necessary.
- a surfactant or an emulsifier include, but are not limited to, polysorbate 80, polyoxyl 40 stearate, lauromacrogol, and the like.
- the method of using the pharmaceutical composition according to the present disclosure may vary depending on symptoms, age, administration method, and the like.
- the method of use is not limited to these, but in one or a plurality of embodiments, the concentration of the compound represented by the formula (I), which is an active ingredient, is intermittently such that the concentration in the body is between 100 nM and 1 mM.
- it can be administered orally, transdermally, submucosally, subcutaneously, intramuscularly, intravascularly, intracerebrally, or intraperitoneally.
- the lower limit in the case of oral administration, is 0.01 mg as converted to the compound represented by formula (I) per day for a subject (adult if human), Or 0.1 mg, and the upper limit is 2000 mg, 500 mg, or 100 mg divided into 1 time or several times and administered according to symptoms.
- the lower limit in the case of intravenous administration, is 0.001 mg, or preferably 0.01 mg, and the upper limit is 500 mg per day for a subject (adult if human). Alternatively, 50 mg may be divided into one or several times and administered according to symptoms.
- the present disclosure relates to a method for ameliorating pain, inhibiting progression and / or treating comprising administering a pharmaceutical composition according to the present disclosure to a subject in need.
- the subject includes mammals, mammals other than humans, or humans, or mammals that exhibit pain symptoms, mammals other than humans, or humans.
- the administration method of the pharmaceutical composition concerning this indication, it can apply to the usage method of the above-mentioned pharmaceutical composition in one or some embodiment.
- W, X, Y, and Z are each independently a hydrogen atom, a halogen atom, a substituted or unsubstituted amino group, an azide group, a cyano group, a nitro group, a hydroxyl group, or a carbon number of 1 -6 linear, branched or cyclic alkyloxy groups, substituted or unsubstituted aryloxy groups, substituted or unsubstituted heteroaryloxy groups, mercapto groups, straight chain, branched or cyclic groups having 1-6 carbon atoms Alkylthio group, substituted or unsubstituted arylthio group, substituted or unsubstituted heteroarylthio group, linear or branched or cyclic alkyl group having 1 to 6
- a compound represented by the following formula (II), a prodrug thereof, or a pharmaceutically acceptable salt thereof [In the formula (II), X 1 and Y 1 are each independently a halogen atom, a substituted or unsubstituted linear or branched or cyclic alkyl group having 1 to 6 carbon atoms, Z 1 and W 1 are each independently a hydrogen atom, a halogen atom, a hydroxyl group, a linear, branched or cyclic alkyloxy group having 1-6 carbon atoms, a substituted or unsubstituted straight chain having 1-6 carbon atoms. A chain or branched or cyclic alkyl group.
- a pharmaceutical composition comprising the compound according to [A1] or [A2] or a prodrug thereof or a pharmaceutically acceptable salt thereof as an active ingredient.
- A4 The pharmaceutical composition according to [A3] for improvement of pain, inhibition of progression, and / or treatment.
- [A6] The pharmaceutical composition according to [A4] or [A5], wherein the pain is inflammatory pain and / or neuropathic pain.
- A7 The pharmaceutical composition according to any one of [A3] to [A6] for analgesic action via an opioid receptor.
- [A8] Use of the compound according to [A1] or [2] or a prodrug thereof or a pharmaceutically acceptable salt thereof for producing the pharmaceutical composition according to any one of [A3] to [A7] .
- [A9] [A1] or [A1] in a method for improving pain, suppressing progression, and / or treatment comprising administering the pharmaceutical composition according to any one of [A3] to [A7] to a subject in need
- Use of the compound according to [2] or a prodrug thereof or a pharmaceutically acceptable salt thereof, or administration of the pharmaceutical composition according to any of [A3] to [A7] to a subject in need A method involving that.
- [A10] A method for improving pain, suppressing progression, and / or treating the subject comprising administering the pharmaceutical composition according to any one of [A3] to [A7] to a subject in need.
- Compound 1 was synthesized as follows. Heat a solution of 5-fluoro-2-methylbenzothiazole (48.8 g, 292 mmol, commercial product) in ethyl iodide (50.0 mL, 622 mmol, commercial product) for 72 hours Reflux (oil bath temperature 100 ° C.).
- Production Example 2 Production of Compound 2 Compound 2 was synthesized according to the method described in the literature (M. Muraki, et al., Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks, The Journal of Biological Chemistry, 2004, 279, 24246-24254, or WO 2010010797 A1). did.
- Compound 3 was synthesized as follows. A solution of 6-methoxy-2-methylbenzothiazole (201 mg, 1.12 mmol, commercial product) in ethyl iodide (2.00 mL, 24.6 mmol, commercial product) is heated for 24 hours. Reflux (oil bath temperature 100 ° C.).
- Compound 5 was synthesized as follows. A solution of 5-bromo-2-methylbenzothiazole (5.11 g, 22.4 mmol, commercial product) in ethyl iodide (3.70 mL, 46.3 mmol, commercial product) is heated for 72 hours. Reflux (oil bath temperature 100 ° C.).
- a solution of Compound 2 was prepared by dissolving Compound 2 in 99% DMSO and then diluting with physiological saline (0.2% DMSO in physiological saline). The result is shown in FIG. FIG. 3A shows the result of examining the threshold of escape reflex behavior for mechanical stimulation, and FIG. 3B shows the latency for thermal stimulation. As shown in FIG. 3, pain was significantly suppressed by administration of Compound 2.
- a solution of compound 3 was prepared by dissolving compound 3 in 99% DMSO and then diluting with physiological saline (0.2% DMSO in physiological saline). The result is shown in FIG. As shown in FIG. 4, administration of Compound 3 significantly suppressed pain.
- composition 2% DMSO and 1% Tween 80 TM physiological saline in which Compound 1 and the following opioid antagonist were dissolved were intraperitoneally administered in an amount of 0.01 mL per gram body weight (about 0 per mouse). 2 mL solution was administered).
- Compound 1 was prepared so as to be 1 nmol per gram of mouse body weight.
- the opioid antagonist was prepared so that it might become 20 nmol per 1 g body weight of a mouse
- Opioid antagonist MNTX Methylnaltrexone bromide Antagonists selective for ⁇ -opioid and ⁇ -opioid receptors. The blood-brain barrier does not pass.
- Opioid antagonist NAL-M Naloxone methiodide Non-selective antagonist for opioid receptors. The blood-brain barrier does not pass.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Pain & Pain Management (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
炎症性疼痛は、侵害受容器を介した侵害受容性疼痛であり、組織損傷部位に放出された炎症性メディエーターによって引き起こされる痛みといえる。炎症性疼痛のメカニズムは以下のように考えられている。すなわち、組織が損傷されて炎症が生じるとブラジキニン、ATP、プロトンなどの発痛物質、及び/又は、プロスタグランジン、セロトニン、ヒスタミン、炎症性サイトカイン等が放出され、絶え間なく自発痛が発生する。さらに、侵害受容器の過敏化により痛覚過敏が生じる。また、侵害受容器の過敏化のメカニズムとして、イオンチャネル、特にカプサイシン受容体として知られるTRPV1チャネルのリン酸化が報告されている。
W、X、Y、及びZは、それぞれ独立して、水素原子、ハロゲン原子、置換若しくは無置換のアミノ基、アジド基、シアノ基、ニトロ基、水酸基、炭素数1―6の直鎖若しくは分枝若しくは環状のアルキルオキシ基、置換若しくは無置換のアリールオキシ基、置換若しくは無置換のヘテロアリールオキシ基、メルカプト基、炭素数1―6の直鎖若しくは分枝若しくは環状のアルキルチオ基、置換若しくは無置換のアリールチオ基、置換若しくは無置換のヘテロアリールチオ基、炭素数1―6の直鎖若しくは分枝若しくは環状のアルキル基、ベンジル若しくはヘテロアリールメチル基、置換若しくは無置換のアリール基、又は置換若しくは無置換のヘテロアリール基である。]
ミン塩などが挙げられる。
本開示は、一態様において、式(I)で表される化合物若しくはそのプロドラッグ又はそれらの製薬上許容される塩を有効成分として含有する医薬組成物に関する。
本開示は、一態様において、本開示にかかる医薬組成物を必要とされる対象に投与することを含む、疼痛の改善、進行抑制、及び/又は、治療方法に関する。前記対象は、一又は複数の実施形態において、哺乳類、ヒトを除く哺乳類、若しくはヒト、又は、疼痛の症状を示す哺乳類、ヒトを除く哺乳類、若しくはヒトが挙げられる。本開示にかかる医薬組成物の投与方法については、一又は複数の実施形態において、前述の医薬組成物の使用方法に準じることができる。
[A1] 下記式(I)で表される化合物若しくはそのプロドラッグ又はそれらの製薬上許容される塩。
[A2] 下記式(II)で表される化合物若しくはそのプロドラッグ又はそれらの製薬上許容される塩。
X1及びY1は、それぞれ独立して、ハロゲン原子、置換若しくは無置換の炭素数1―6の直鎖若しくは分枝若しくは環状のアルキル基であり、
Z1及びW1は、それぞれ独立して、水素原子、ハロゲン原子、水酸基、炭素数1―6の直鎖若しくは分枝若しくは環状のアルキルオキシ基、置換若しくは無置換の炭素数1―6の直鎖若しくは分枝若しくは環状のアルキル基である。]
[A3] [A1]又は[A2]に記載の化合物若しくはそのプロドラッグ又はそれらの製薬上許容される塩を有効成分として含有する医薬組成物。
[A4] 疼痛の改善、進行抑制、及び/又は、治療のための、[A3]記載の医薬組成物。
[A5]
[A6] 疼痛が、炎症性疼痛及び/又は神経障害性疼痛である、[A4]又は[A5]記載の医薬組成物。
[A7] オピオイド受容体を介した鎮痛作用のための、[A3]から[A6]のいずれかに記載の医薬組成物。
[A8] [A3]から[A7]のいずれかに記載の医薬組成物を製造するための[A1]又は[2]に記載の化合物若しくはそのプロドラッグ又はそれらの製薬上許容される塩の使用。
[A9] [A3]から[A7]のいずれかに記載の医薬組成物を必要とされる対象に投与することを含む疼痛の改善、進行抑制、及び/又は、治療方法における、[A1]又は[2]に記載の化合物若しくはそのプロドラッグ又はそれらの製薬上許容される塩の使用、或いは、[A3]から[A7]のいずれかに記載の医薬組成物を必要とされる対象に投与することを含む方法。
[A10] [A3]から[A7]のいずれかに記載の医薬組成物を必要とされる対象に投与することを含む、疼痛の改善、進行抑制、及び/又は、治療方法。
次に、アルゴン雰囲気下、ヨウ化3-エチル-5-フルオロ-2-メチルベンゾチアゾリウム(3-ethyl-5-fluoro-2-methylbenzothiazolium iodide)(32.3 g,100 mmol)のアセトニトリル(150 mL)溶液に、無水酢酸(acetic anhydride)(22.5 mL, 236 mmol、商用品)、トリエチルアミン(triethylamine)(32.2 mL, 231 mmol、商用品)を室温にて順次加えた後、3時間加熱還流(油浴温度 80 ℃)した。室温放冷後、この反応混合物に水を加え、酢酸エチル(×3)で抽出し、これを飽和食塩水で洗浄した後、無水硫酸ナトリウムで乾燥した。これを濾過した後、濾液を減圧下で濃縮した。得られた反応粗成生物をシリカゲルカラムクロマトグラフィー(和光純薬、Presep(商標) Silica Gel(HC-N) Type2L、ヘキサン/酢酸エチル=5/1 to 1/1)で精製した後、ヘキサン-酢酸エチルで再結晶し、(1Z)-1-(3-エチル-5-フルオロ-2(3H)-ベンゾチアゾイリデン)-2-プロパノン((1Z)-1-(3-ethyl-5-fluoro-2(3H)-benzothiazolylidene)-2-propanone)(17.8 g,75.2 mmol,75.2%)(化合物1)を無色の針状結晶として得た。融点 179-180 ℃; TLC Rf 0.36 (ヘキサン/酢酸エチル = 7/3); 1H NMR (CDCl3, 400 MHz) δ 1.38 (t, 3H, J = 7.2 Hz), 2.25 (s, 3H),4.01 (q, 2H, J = 7.2 Hz), 5.90 (s, 1 H), 6.82 (dd, 1H, J = 2.4, 9.6Hz), 6.88 (ddd, 1H, J = 2.4, 8.4, 8.4 Hz), 7.48 (dd, 1H, J = 5.2, 8.4 Hz); IR (KBr, cm-1) 978, 1042, 1125, 1192, 1326, 1332, 1354, 1382, 1449, 1453, 1468, 1488, 1492, 1604, 2981.
アルゴン雰囲気下、ヨウ化3-エチル-6-メトキシ-2-メチルベンゾチアゾリウム(3-ethyl-6-methoxy-2-methylbenzothiazolium iodide)(257 mg,0.766 mmol)のアセトニトリル(2 mL)溶液に、無水酢酸(acetic anhydride)(0.170 mL, 1.80 mmol、商用品)、トリエチルアミン(triethylamine)(0.250 mL, 1.79 mmol、商用品)を室温にて順次加えた後、2時間加熱還流(油浴温度 80 ℃)した。室温放冷後、この反応混合物を減圧濃縮し、水を加え、酢酸エチル(×3)で抽出し、これを飽和食塩水で洗浄した後、無水硫酸ナトリウムで乾燥した。これを濾過した後、濾液を減圧下で濃縮した。得られた反応粗成生物をシリカゲルカラムクロマトグラフィー(ヘキサン/酢酸エチル=1/2)で精製し、(1Z)-1-(3-エチル-6-メトキシ-2(3H)-ベンゾチアゾイリデン)プロパン-2-オン((1Z)-1-(3-ethyl-6-methoxy-2(3H)-benzothiazoylidene)-2-propanone)(115 mg,0.461 mmol,60.2%)(化合物3)を淡黄色固体として得た。融点 134-135 ℃; TLC Rf 0.27 (ヘキサン/酢酸エチル = 1/2); 1H NMR (CDCl3, 400 MHz) δ 1.36 (t, 3H, J = 7.2 Hz), 2.23 (s, 3H), 4.03 (q, 2H, J = 7.2 Hz), 5.82 (s, 1 H), 6.91 (dd, 1H, J = 2.5, 8.7 Hz), 7.01 (d,1H, J = 8.7 Hz), 7.13 (d, 1H, J = 2.5 Hz); IR (KBr, cm-1) 720, 760, 801, 959, 1020, 1046, 1136, 1188, 1219, 1258, 1273, 1298, 1327, 1358, 1472, 1487, 1590, 1603, 2342, 2361, 2980.
次に、アルゴン雰囲気下、ヨウ化5-ブロモ-3-エチル-2-メチルベンゾチアゾリウム(5-bromo-3-ethyl-2-methylbenzothiazolium iodide)(4.10 g,10.7 mmol)のアセトニトリル(18 mL)溶液に、無水酢酸(acetic anhydride)(2.41 mL, 25.5 mmol、商用品)、トリエチルアミン(triethylamine)(3.44 mL, 24.7 mmol、商用品)を室温にて順次加えた後、2時間加熱還流(油浴温度 80 ℃)した。室温放冷後、この反応混合物に塩化メチレン300 mLを加え、塩化アンモニウム水溶液と飽和食塩水で順次洗浄し、無水硫酸ナトリウムで乾燥させた。これを濾過した後、濾液を減圧下で濃縮した。得られた反応粗成生物をシリカゲルカラムクロマトグラフィー(和光純薬、Presep(商標) Silica Gel(HC-N) Type L、ヘキサン/酢酸エチル=5/1 to 1/2)で精製した後、ヘキサン-酢酸エチルで再結晶し、(1Z)-1-(5-ブロモ-3-エチル-2(3H)-ベンゾチアゾイリデン)-2-プロパノン((1Z)-1-(5-bromo-3-ethyl-2(3H)-benzothiazoylidene)-2-propanone)(2.72 g,9.13 mmol,85.3%)(化合物5)を無色固体として得た。融点 184-185 ℃; TLC Rf 0.39 (ヘキサン/酢酸エチル = 7/3); 1H NMR (CDCl3, 400 MHz) δ 1.38 (t, 3H, J = 7.2 Hz), 2.25 (s, 3H), 4.02 (q, 2H, J = 7.2 Hz), 5.90 (s, 1 H), 7.22 (d, 1H, J = 1.6 Hz), 7.27 (dd, 1H, J = 1.6, 8.4Hz), 7.41 (d, 1H, J = 8.4 Hz); IR (KBr, cm-1) 800, 850, 964, 1086, 1139, 1188, 1299, 1328, 1353, 1382, 1450, 1467, 1489, 1588, 1614, 2978.
次に、アルゴン雰囲気下、ヨウ化5-クロロ-3-エチル-2-メチルベンゾチアゾリウム(5-chloro-3-ethyl-2-methylbenzothiazolium iodide)(4.95 g,14.6 mmol)のアセトニトリル(25 mL)溶液に、無水酢酸(acetic anhydride)(3.29 mL, 34.8 mmol、商用品)、トリエチルアミン(triethylamine)(4.70 mL, 33.8 mmol、商用品)を室温にて順次加えた後、3時間加熱還流(油浴温度 80 ℃)した。室温放冷後、この反応混合物に塩化メチレン300 mLを加え、塩化アンモニウム水溶液と飽和食塩水で順次洗浄し、無水硫酸ナトリウムで乾燥させた。これを濾過した後、濾液を減圧下で濃縮した。得られた反応粗成生物をシリカゲルカラムクロマトグラフィー(和光純薬、Presep(商標) Silica Gel(HC-N) Type L、ヘキサン/酢酸エチル=5/1 to 1/2)で精製した後、ヘキサン-酢酸エチルで再結晶し、(1Z)-1-(5-クロロ-3-エチル-2(3H)-ベンゾチアゾイリデン)-2-プロパノン((1Z)-1-(5-chloro-3-ethyl-2(3H)-benzothiazoylidene)propan-2-one)(3.42 g,75.2 mmol,92.2%)(化合物6)を無色固体として得た。融点 175-176 ℃; TLC Rf 0.43 (ヘキサン/酢酸エチル = 7/3); 1H NMR (CDCl3, 400 MHz) δ 1.38 (t, 3H, J = 7.2 Hz), 2.25 (s, 3H), 4.02 (q, 2H, J = 7.2 Hz), 5.90 (s, 1 H), 7.07 (d, 1H, J = 1.6 Hz), 7.13 (dd, 1H, J = 1.6, 8.4 Hz), 7.47 (d, 1H, J = 8.4 Hz); IR (KBr, cm-1) 839, 938, 963, 1044, 1088, 1140, 1189, 1297, 1314, 1328, 1353, 1382, 1463, 1492, 1582, 1613, 2979.
カラゲニンを足底皮下投与すると、数時間後にかけて急性炎症が生じ、それに伴い機械的刺激、熱刺激に対する過敏現象が生じる。このカラゲニン誘発による炎症性疼痛モデルマウスに化合物1を有効成分とする治療薬を投与し、疼痛を評価した。
すなわち、マウス(雄性C57BL/6J、6~8週齢)の後肢足底部へカラゲニンを皮下投与した7時間後に化合物1を経口投与し、化合物1の投与1時間後に機械的アロディニアの治療効果を確認した具体的な条件は以下の通りとした。
マウス:C57BL/6J、オス、8週齢、n=4(片足ずつでn=8)
疼痛の誘導:25μLの2%λ-カラゲニンを含む生理食塩水を後肢底部皮下に注入して誘導した。
治療薬投与:マウスの体重1gあたり1nmolの化合物1となるように、マウスの体重20gあたり0.2mlの化合物1の溶液を経口投与した。なお、化合物1の溶液は、化合物1を99%DMSOに溶解した後に生理食塩水で希釈して調製した(0.2%DMSO in 生理食塩水)。
疼痛の評価:von Freyテストにより評価した。すなわち、様々な太さのvon Freyフィラメントの先端でマウスの後肢底部を機械的に刺激し、マウスが逃避行動を起こす刺激の荷重を調べた。その結果を図1に示す。
図1に示すとおり、化合物1の投与によって疼痛が有意に抑制された。一方、化合物1に換えてDMSOを使用した例では、投与による疼痛の抑制が確認されなかった。
マウス(雄性C57BL/6J、6~8週齢)の片側後肢足底にカラゲニン(2%, 25μl)を皮下投与する前後で、熱刺激を与え、後肢の逃避反射行動の潜時を測定した。カラゲニンによる熱性痛覚過敏現象出現を投与後6時間まで確認した後、化合物1又は溶解に使用した溶媒(veh.)を経口投与し(マウスの体重1gあたり1pmol又は10pmol)、その後2時間まで効果を検討した。その結果を図2に示す。
図2に示すとおり、化合物1の投与によって疼痛が有意に抑制された。一方、化合物1に換えてDMSOを使用した例では、投与による疼痛の抑制が確認されなかった。
マウス(雄性C57BL/6J、6~8週齢)の片側後肢足底にカラゲニン(2%, 25μl)を皮下投与する前後で、機械刺激或いは熱刺激を与え、後肢の逃避反射行動の閾値(機械刺激)と潜時(熱刺激)を測定した。カラゲニンによる機械的アロディニア現象或いは熱性痛覚過敏出現を投与後6時間まで確認した後、化合物2を髄腔内投与し(0.1 pmol、1 pmol又は10 pmol)、その後3時間まで効果を検討した。なお、化合物2の溶液は、化合物2を99%DMSOに溶解した後に生理食塩水で希釈して調製した(0.2%DMSO in 生理食塩水)。
その結果を図3に示す。図3Aは機械刺激に対する逃避反射行動の閾値、図3Bは熱刺激に対する潜時を調べた結果である。
図3に示すとおり、化合物2の投与によって疼痛が有意に抑制された。
完全フロイントアジュバンド(CFA)を足底皮下投与すると、カラゲニンモデルより長期間持続する遷延性炎症を生じ、それに伴い機械的刺激、熱刺激に対する過敏現象が生じる。このCFAモデルマウスを用い、化合物3の疼痛治療効果を評価した。
マウス(雄性C57BL/6J、6~8週齢)の片側後肢足底にCFA(25μl)を皮下投与する前後に機械刺激を与え、後肢の逃避反射行動の閾値を測定した。CFAによる機械的アロディニア現象出現を投与後3日後に確認し、化合物3を髄腔内投与した後、3時間まで効果を検討した。なお、化合物3の溶液は、化合物3を99%DMSOに溶解した後に生理食塩水で希釈して調製した(0.2%DMSO in 生理食塩水)。その結果を図4に示す。
図4に示すとおり、化合物3の投与によって疼痛が有意に抑制された。
マウス(雄性C57BL/6J、6~8週齢)の片側後肢足底にカラゲニン(2%, 25μl)を皮下投与する前後で、機械刺激あるいは熱刺激を与え、後肢の逃避反射行動の閾値(機械刺激)と潜時(熱刺激)を測定した。カラゲニンによる機械的アロディニア現象あるいは熱性痛覚過敏出現を投与後6時間まで確認した後、化合物4を髄腔内投与し、その後3時間まで効果を検討した。なお、化合物4の溶液は、化合物4を99%DMSOに溶解した後に生理食塩水で希釈して調製した(0.2%DMSO in 生理食塩水)。その結果を図5に示す。
図5に示すとおり、化合物4の投与によって疼痛が有意に抑制された。
マウス(雄性C57BL/6J、6~8週齢)の片側後肢足底にカラゲニン(2%, 25μl)を皮下投与する前後で、熱刺激を与え、後肢の逃避反射行動の潜時を測定した。カラゲニンによる熱性痛覚過敏現象出現を投与後6時間まで確認した後、化合物5を髄腔内投与し、その後3時間まで効果を検討した。なお、化合物5の溶液は、化合物5を99%DMSOに溶解した後に生理食塩水で希釈して調製した(0.2%DMSO in 生理食塩水)。その結果を図6に示す。
図6に示すとおり、化合物5の投与によって疼痛が有意に抑制された。
マウス(雄性C57BL/6J、6~8週齢)の片側後肢足底にカラゲニン(2%, 25μl)を皮下投与する前後で、熱刺激を与え、後肢の逃避反射行動の潜時を測定した。カラゲニンによる熱性痛覚過敏現象出現を投与後6時間まで確認した後、化合物6を髄腔内投与し、その後3時間まで効果を検討した。なお、化合物6の溶液は、化合物6を99%DMSOに溶解した後に生理食塩水で希釈して調製した(0.2%DMSO in 生理食塩水)。その結果を図7に示す。
図7に示すとおり、化合物6の投与によって疼痛が有意に抑制された。
マウスの後肢底部へカラゲニンを皮下注射し、7時間後に化合物1とオピオイド拮抗薬とを同時に腹腔内投与し、投与後1時間後と3時間後に機械的アロディニアの治療効果を評価した。具体的な条件は以下の通りとした。
マウス:C57BL/6J、オス、8週齢
疼痛の誘導:20μLの2%λ-カラゲニンを含む生理食塩水を後肢底部皮下に注入して誘導した。
治療薬投与:化合物1及び下記オピオイド拮抗薬が溶解した2%DMSO、1%Tween80(商標)の生理食塩水を体重1gあたり0.01mLの分量で腹腔内投与した(マウス1匹あたり、約0.2mLの溶液を投与した)。化合物1は、マウスの体重1gあたり1nmolとなるように調製した。オピオイド拮抗薬は、マウスの体重1gあたり20nmolとなるように調製した。
μ-オピオイド受容体とκ-オピオイド受容体に選択的な拮抗薬。血液脳関門は通過しない。
オピオイド受容体に対する非選択的な拮抗薬。血液脳関門は通過しない。
図8に示すとおり、化合物1の疼痛の鎮痛作用が、末梢性のオピオイド拮抗薬で鎮痛作用が阻害された。よって、化合物1の疼痛の鎮痛作用は、オピオイド受容体を介すると考えられる。
Claims (10)
- 下記式(I)で表される化合物若しくはそのプロドラッグ又はそれらの製薬上許容される塩。
W、X、Y、及びZは、それぞれ独立して、水素原子、ハロゲン原子、置換若しくは無置換のアミノ基、アジド基、シアノ基、ニトロ基、水酸基、炭素数1―6の直鎖若しくは分枝若しくは環状のアルキルオキシ基、置換若しくは無置換のアリールオキシ基、置換若しくは無置換のヘテロアリールオキシ基、メルカプト基、炭素数1―6の直鎖若しくは分枝若しくは環状のアルキルチオ基、置換若しくは無置換のアリールチオ基、置換若しくは無置換のヘテロアリールチオ基、炭素数1―6の直鎖若しくは分枝若しくは環状のアルキル基、ベンジル若しくはヘテロアリールメチル基、置換若しくは無置換のアリール基、又は置換若しくは無置換のヘテロアリール基である。] - 請求項1又は2記載の化合物若しくはそのプロドラッグ又はそれらの製薬上許容される塩を有効成分として含有する医薬組成物。
- 疼痛の改善、進行抑制、及び/又は、治療のための、請求項3記載の医薬組成物。
- 疼痛が、炎症性疼痛及び/又は神経障害性疼痛である、請求項4又は5に記載の医薬組成物。
- オピオイド受容体を介した鎮痛作用のための、請求項3から6のいずれかに記載の医薬組成物。
- 請求項3から7のいずれかに記載の医薬組成物を製造するための請求項1又は2記載の化合物若しくはそのプロドラッグ又はそれらの製薬上許容される塩の使用。
- 請求項3から7のいずれかに記載の医薬組成物を必要とされる対象に投与することを含む疼痛の改善、進行抑制、及び/又は、治療方法における、請求項1記載の化合物若しくはそのプロドラッグ又はそれらの製薬上許容される塩又は請求項3から6のいずれかに記載の医薬組成物の使用。
- 請求項3から7のいずれかに記載の医薬組成物を必要とされる対象に投与することを含む、疼痛の改善、進行抑制、及び/又は、治療方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015553602A JP6531330B2 (ja) | 2013-12-18 | 2014-12-18 | 疼痛に関する化合物及び医薬組成物 |
US15/105,985 US9745275B2 (en) | 2013-12-18 | 2014-12-18 | Pain-related compound and medical composition |
CN201480070279.9A CN105829291B (zh) | 2013-12-18 | 2014-12-18 | 与疼痛有关的化合物及医药组合物 |
EP14871323.3A EP3085698B1 (en) | 2013-12-18 | 2014-12-18 | Pain-related compound and medicinal composition |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-261396 | 2013-12-18 | ||
JP2013261396 | 2013-12-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015093567A1 true WO2015093567A1 (ja) | 2015-06-25 |
Family
ID=53402909
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/083569 WO2015093567A1 (ja) | 2013-12-18 | 2014-12-18 | 疼痛に関する化合物及び医薬組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9745275B2 (ja) |
EP (1) | EP3085698B1 (ja) |
JP (1) | JP6531330B2 (ja) |
CN (1) | CN105829291B (ja) |
WO (1) | WO2015093567A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022065354A1 (ja) | 2020-09-23 | 2022-03-31 | 国立大学法人京都大学 | アルファ2アドレナリン受容体アンタゴニスト |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5089367A (ja) * | 1973-12-14 | 1975-07-17 | ||
JP2004002352A (ja) * | 2002-03-29 | 2004-01-08 | Santen Pharmaceut Co Ltd | 2−フェニルベンゾチアゾリン誘導体からなるκオピオイド受容体アゴニスト |
US20050171026A1 (en) | 2004-01-09 | 2005-08-04 | Tokyo Medical And Dental University | Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction |
US20080255123A1 (en) * | 2006-10-12 | 2008-10-16 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
JP2008539269A (ja) | 2005-04-28 | 2008-11-13 | セラクエスト バイオサイエンシズ エルエルシー | 疼痛を治療するための方法および組成物 |
WO2009085226A2 (en) * | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibitors of cdc2-like kinases (clks) and methods of use thereof |
WO2010010797A1 (ja) | 2008-07-23 | 2010-01-28 | 株式会社キノファーマ | Dyrkを阻害する化合物を含有する医薬組成物 |
WO2013168826A1 (ja) * | 2012-05-09 | 2013-11-14 | 国立大学法人大阪大学 | 炎症関連フィードバックループが関与する疾患又は障害の予防又は治療剤のスクリーニング方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003082840A1 (en) | 2002-03-29 | 2003-10-09 | Santen Pharmaceutical Co., Ltd. | κ-OPIOID RECEPTOR AGONIST COMPRISING 2-PHENYLBENZOTHIAZOLINE DERIVATIVE |
CA2631713A1 (en) | 2005-12-02 | 2007-09-13 | Sirtris Pharmaceuticals, Inc. | Modulators of cdc2-like kinases (clks) and methods of use thereof |
-
2014
- 2014-12-18 CN CN201480070279.9A patent/CN105829291B/zh active Active
- 2014-12-18 WO PCT/JP2014/083569 patent/WO2015093567A1/ja active Application Filing
- 2014-12-18 JP JP2015553602A patent/JP6531330B2/ja active Active
- 2014-12-18 EP EP14871323.3A patent/EP3085698B1/en active Active
- 2014-12-18 US US15/105,985 patent/US9745275B2/en active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5089367A (ja) * | 1973-12-14 | 1975-07-17 | ||
JP2004002352A (ja) * | 2002-03-29 | 2004-01-08 | Santen Pharmaceut Co Ltd | 2−フェニルベンゾチアゾリン誘導体からなるκオピオイド受容体アゴニスト |
US20050171026A1 (en) | 2004-01-09 | 2005-08-04 | Tokyo Medical And Dental University | Therapeutic composition of treating abnormal splicing caused by the excessive kinase induction |
JP2008539269A (ja) | 2005-04-28 | 2008-11-13 | セラクエスト バイオサイエンシズ エルエルシー | 疼痛を治療するための方法および組成物 |
US20080255123A1 (en) * | 2006-10-12 | 2008-10-16 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
WO2009085226A2 (en) * | 2007-12-21 | 2009-07-09 | Sirtris Pharmaceuticals, Inc. | Inhibitors of cdc2-like kinases (clks) and methods of use thereof |
WO2010010797A1 (ja) | 2008-07-23 | 2010-01-28 | 株式会社キノファーマ | Dyrkを阻害する化合物を含有する医薬組成物 |
WO2013168826A1 (ja) * | 2012-05-09 | 2013-11-14 | 国立大学法人大阪大学 | 炎症関連フィードバックループが関与する疾患又は障害の予防又は治療剤のスクリーニング方法 |
Non-Patent Citations (3)
Title |
---|
KURIHARA, T. ET AL.: "Alleviation of behavioral hypersensitivity in mouse models of inflammatory pain with two structurally different casein kinase 1 (CK1) inhibitors", MOLECULAR PAIN, vol. 10, pages 17 /1 - 17/13, XP021180976 * |
M. MURAKI ET AL.: "Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, 2004, pages 24246 - 24254, XP055192700, DOI: doi:10.1074/jbc.M314298200 |
MURAKI M. ET AL.: "Manipulation of Alternative Splicing by a NewlyDeveloped Inhibitor of Clks", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, no. 23, 2004, pages 24246 - 24254, XP055192700 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022065354A1 (ja) | 2020-09-23 | 2022-03-31 | 国立大学法人京都大学 | アルファ2アドレナリン受容体アンタゴニスト |
KR20230074209A (ko) | 2020-09-23 | 2023-05-26 | 고쿠리츠 다이가쿠 호진 교토 다이가쿠 | 알파 2 아드레날린 수용체 안타고니스트 |
Also Published As
Publication number | Publication date |
---|---|
JP6531330B2 (ja) | 2019-06-19 |
CN105829291A (zh) | 2016-08-03 |
EP3085698A1 (en) | 2016-10-26 |
US9745275B2 (en) | 2017-08-29 |
JPWO2015093567A1 (ja) | 2017-03-23 |
EP3085698B1 (en) | 2019-11-13 |
CN105829291B (zh) | 2019-05-21 |
US20170029389A1 (en) | 2017-02-02 |
EP3085698A4 (en) | 2017-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102129247B1 (ko) | 오피오이드 수용체 리간드와 그 용도 및 제조방법 | |
DE69813896T2 (de) | Alpha-aminoamidderivate die als analgetische mittel nützlich sind | |
KR101855357B1 (ko) | 오피오이드 유도성 통각과민에서의 시그마 리간드의 용도 | |
RU2495041C2 (ru) | Диэфирные пролекарства налмефена | |
JP5860895B2 (ja) | 5−メチル−1−(ナフタレン−2−イル)−1h−ピラゾール誘導体 | |
WO2015083750A1 (ja) | 神経新生に関する化合物及び医薬組成物 | |
CN105792821B (zh) | 包含1-茚满硫酰胺衍生物的疼痛治疗剂和/或预防剂 | |
CN112118844B (zh) | 含吲哚化合物的多发性硬化症治疗剂或预防剂 | |
WO2010034269A1 (zh) | 2,5-二羟基甲基-3,6-二甲基吡嗪及其衍生物在制药中的应用 | |
CN105497019A (zh) | 胺类化合物治疗疼痛的医药用途 | |
WO2015093567A1 (ja) | 疼痛に関する化合物及び医薬組成物 | |
EP1871364A1 (en) | Methods for treating or preventing acute myelogenous leukemia | |
JP2008137892A (ja) | 止痒剤 | |
WO2009097774A1 (zh) | 芳基哌嗪衍生物在制备用于治疗疼痛的药物中的用途 | |
ES2398225T3 (es) | Derivados de éster de un ácido DECAHIDROISOQUINOLIN-3-CARBOXÍLICO como analgésicos | |
JP6691135B2 (ja) | ジアリールメチリデンピペリジン誘導体およびデルタオピオイド受容体アゴニストとしてそれらの使用 | |
CN101811974B (zh) | 4-(3-(二甲氨基)丙氧基)-3,5-二甲氧基苯甲酸、其制法及医药用途 | |
JP2009235069A (ja) | 3’,5−ジ−2−プロペニル−(1,1’−ビフェニル)−2,4’−ジオールを有効成分として含有する視神経障害の予防又は治療剤 | |
JP4598674B2 (ja) | 統合失調症治療剤 | |
KR20170106485A (ko) | 요산 또는 통풍 질환의 예방 또는 치료 | |
JP5782299B2 (ja) | 神経因性疼痛用鎮痛剤 | |
TW202333753A (zh) | 心腦血管藥物及其應用 | |
WO2010029996A1 (ja) | 医薬組成物 | |
WO2005007154A1 (ja) | 疼痛の予防及び/または治療剤 | |
WO2013075624A1 (zh) | 甘氨酸重摄取抑制剂及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14871323 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015553602 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15105985 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2014871323 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014871323 Country of ref document: EP |